Status:
NOT_YET_RECRUITING
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Sepsis-induced Coagulopathy (SIC)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In sepsis, the body is prone to coagulation system disorders, which may progress to sepsis-induced coagulopathy (SIC). When SIC is persistent and cannot be corrected, it often sequentially develops in...
Eligibility Criteria
Inclusion
- Adults (Age ≥ 18 years);
- Patients with SIC Undergoing Hemofiltration.
Exclusion
- Individuals under the age of 18, pregnant women, and breastfeeding mothers;
- Patients with a history of high sensitivity to nafamostat mesylate (those who have experienced significant bleeding complications from previous use of nafamostat mesylate);
- Fibrinogen \< 1.5 g/L;
- Patients with bleeding or high risk of bleeding:
- Those in the acute phase of trauma or with active bleeding (e.g., flail chest, obvious contusions of the lungs, liver, spleen, retroperitoneal bleeding, pelvic fractures, etc.); Those with a history of severe head trauma, intracranial surgery, stroke, cerebral aneurysm, or arteriovenous malformation within one month prior to enrollment; Those with a history of congenital bleeding disorders: such as hemophilia; Those with underlying fulminant hepatitis, decompensated cirrhosis, or other severe liver diseases.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT06994312
Start Date
July 1 2025
End Date
December 1 2028
Last Update
May 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.